The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians

RECOMMENDED

Genitourinary Cancer

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

JAMA Oncol.

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM

doi: 10.1001/

Genitourinary Cancer

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy

Eur Urol.

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J

doi: 10.1016/j.eururo.2020.07.003.

RECOMMENDED

Radio-Oncology

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease

doi: 10.1007/s00345-018-2551-9.

Genitourinary Cancer

Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer

Cancer Treat Rev.

Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M

doi: 10.1016/

Gastrointestinal Cancer

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Lancet.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A

doi: 10.1016/S0140-6736

Genitourinary Cancer

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis

Eur J Cancer

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, Shariat SF, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

doi: 10.1016/j.ejca.2021.03.049

Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database

Surgery.

Shubert CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, Smoot RL, Kendrick ML, Nagorney DM, Farnell MB.

doi: 10.1016/j.surg.2016.06.010.

Head and Neck CancerSkin CancerCOVID-19

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Eur J Cancer

Faron M, Cheugoua-Zanetsie AM, Thirion P, Nankivell M, Winter K, Cunningham D, Van der Gaast A, Law S, Langley R, de Vathaire F, Valmasoni M, Mauer M, Roth J, Gebski V, Burmeister BH, Paoletti X, van Sandick J, Fu J, Ducreux M, Blanchard P, Tierney J, Pignon JP, Michiels S, MANATEC-02 collaborative group.

doi: 10.1016/j.ejca.2021.08.014

Genitourinary Cancer

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

Front Oncol.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN

doi: 10.3389/fonc.2018.00463.

Related content

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease

Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis

Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database